share_log

泰恩康(301263.SZ):目前盐酸毛果芸香碱滴眼液临床试验按计划进行中,争取在今年年底前完成全部患者入组

Tianeng Kang (301263.SZ): Currently, the clinical trial of hydrochloride pilocarpine eye drops is proceeding as planned, aiming to complete the enrollment of all patients by the end of this year.

Gelonghui Finance ·  Nov 18, 2024 18:26

On November 18, Gelonghui reported that Tainkang (301263.SZ) recently stated in an investor relations event that the company's eye drops containing pilocarpine hydrochloride for treating presbyopia in adults received approval for clinical trials in March 2024, with the first subject enrolled in June 2024. The clinical trials are currently proceeding as planned, and the company will strive to advance the clinical progress, aiming to complete the enrollment of all patients by the end of this year; as of now, there are no similar products approved for sale in the domestic market.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment